Denamarin Tablets for Medium Dogs 5-15kg - 30 pk (225mg)

Denamarin is a high-level liver support with market-leading bioavailability and exceptional stability. Denamarin is the number one veterinarian-recommended liver support brand for dogs and cats*. Veterinarians suggest it to deliver anti-oxidant support for pets with impaired liver function, liver illness, and to help in liver detoxification mechanisms.

*Denamarin has taken the position of Denosyl in Australia*

Denamarin's unique composition combines the advantages of S-Adenosylmethionine (SAMe) and Silybin in a single pill when maximal liver support is required.

• Denamarin's particular silybin has been demonstrated to have higher bioavailability in dogs and cats than standardised milk thistle, which is widely accessible in health food shops and over-the-counter in pharmacies.

• SAMe and Silybin, two active substances, provide complete liver support.

• Has been demonstrated to protect against the harmful effects of several drugs on the liver.

• Has been found to increase glutathione levels for improved detoxification.

• It has been demonstrated that it protects liver cells from toxins and death while also stimulating cell regeneration.

• Silybin A+B functions as an antioxidant, aiding in the protection against reactive oxygen molecules and oxidative stress.

• Proven large safety margins, strong quality assurance, and guaranteed to match label claims.

Why use Denamarin?

Denamarin is the #1 Vet recommended liver support brand for dogs and cats. It is sold exclusively through veterinary suppliers as adjunctive treatment for liver disease or dysfunction, such as the following:

• Chronic hepatitis

• Hepatic lipidosis

• Cholangiohepatitis

• Paracetamol toxicity

• Corticosteroid use (Note: does not prevent corticosteroid induced hepatic vacuolar change)

• Other acute or chronic hepatopathies, including hepatotoxins and neoplasia.

Denamarin is the #1 vet recommended liver support brand for dogs and cats*. It is sold exclusively through veterinary suppliers as adjunctive treatment for liver disease or dysfunction, such as the following:

• Chronic hepatitis
• Hepatic lipidosis
   
• Cholangiohepatitis
• Paracetamol toxicity
• Corticosteroid use (Note: does not prevent corticosteroid induced hepatic vacuolar change)

•    Other acute or chronic hepatopathies, including hepatotoxins and neoplasia.